HCW Biologics Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
45
- Stock Symbol
-
HCWB
- Share Price
-
$0.30
- (As of Thursday Closing)
HCW Biologics General Information
Description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact Information
Website
www.hcwbiologics.comCorporate Office
- 2929 North Commerce Parkway
- Miramar, FL 33025
- United States
Corporate Office
- 2929 North Commerce Parkway
- Miramar, FL 33025
- United States
HCW Biologics Stock Performance
As of 20-Mar-2025, HCW Biologics’s stock price is $0.30. Its current market cap is $13.4M with 44.5M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $0.30 | $0.31 | $0.21 - $2.52 | $13.4M | 44.5M | 6.24M | -$1.01 |
HCW Biologics Financials Summary
As of 30-Sep-2024, HCW Biologics has a trailing 12-month revenue of $3.5M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 29,265 | 39,181 | 48,911 | 42,774 |
| Revenue | 3,496 | 2,842 | 6,722 | 0 |
| EBITDA | (36,173) | (23,576) | (14,056) | (12,319) |
| Net Income | (37,331) | (24,994) | (14,901) | (12,862) |
| Total Assets | 26,556 | 28,514 | 46,809 | 53,515 |
| Total Debt | 12,803 | 6,304 | 6,410 | 0 |
HCW Biologics Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
HCW Biologics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
HCW Biologics Comparisons
Industry
Financing
Details
HCW Biologics Competitors (12)
One of HCW Biologics’s 12 competitors is Gilead Sciences, a Formerly VC-backed company based in Foster City, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Gilead Sciences | Formerly VC-backed | Foster City, CA | ||||
| Intercept Pharmaceuticals | Formerly VC-backed | Morristown, NJ | ||||
| Genentech | Formerly VC-backed | South San Francisco, CA | ||||
| Cardurion | Venture Capital-Backed | Burlington, MA | ||||
| XyloCor Therapeutics | Venture Capital-Backed | Wayne, PA |
HCW Biologics Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
HCW Biologics Patents
HCW Biologics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| CA-3227318-A1 | Multi-chain chimeric polypeptides and use thereof in the treatment of liver diseases | Pending | 11-Aug-2021 | ||
| CA-3184756-A1 | Methods of treating aging-related disorders | Pending | 01-Jun-2020 | ||
| CA-3181417-A1 | Anti-cd26 proteins and uses thereof | Pending | 29-Apr-2020 | ||
| CA-3169231-A1 | Methods of treating age-related and inflammatory diseases | Pending | 11-Feb-2020 | ||
| CA-3169625-A1 | Chromatography resin and uses thereof | Pending | 11-Feb-2020 | C07K16/36 |
HCW Biologics Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
HCW Biologics Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
HCW Biologics FAQs
-
When was HCW Biologics founded?
HCW Biologics was founded in 2018.
-
Where is HCW Biologics headquartered?
HCW Biologics is headquartered in Miramar, FL.
-
What is the size of HCW Biologics?
HCW Biologics has 45 total employees.
-
What industry is HCW Biologics in?
HCW Biologics’s primary industry is Drug Discovery.
-
Is HCW Biologics a private or public company?
HCW Biologics is a Public company.
-
What is HCW Biologics’s stock symbol?
The ticker symbol for HCW Biologics is HCWB.
-
What is the current stock price of HCW Biologics?
As of 20-Mar-2025 the stock price of HCW Biologics is $0.30.
-
What is the current market cap of HCW Biologics?
The current market capitalization of HCW Biologics is $13.4M.
-
What is HCW Biologics’s current revenue?
The trailing twelve month revenue for HCW Biologics is $3.5M.
-
Who are HCW Biologics’s competitors?
Gilead Sciences, Intercept Pharmaceuticals, Genentech, Cardurion, and XyloCor Therapeutics are some of the 12 competitors of HCW Biologics.
-
What is HCW Biologics’s annual earnings per share (EPS)?
HCW Biologics’s EPS for 12 months was -$1.01.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
